Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
I am listing neuropathic pain therapies that are non-conventional below because there are few, if any, effective conventional neuropathic pain therapies.
I am a long-term survivor of cancer. CIPN is one of the most difficult side effects there is in my experience.
Which brings me to the reason for writing this post. According to research, more than 70% of myeloma patients struggle with chemotherapy-induced peripheral neuropathy (CIPN), yet few effective therapies exist. So when I come across studies like the one linked and excerpted below, that talk about effective CIPN therapies, I write about them.
I am including the list of non-conventional CIPN therapies in case there is one or more therapies that you don’t know about.
Neuropathic pain is a type of chronic pain that results from damage or dysfunction of the nervous system. While conventional treatments such as medications (antidepressants, anticonvulsants), physical therapy, and nerve blocks are commonly used, there are also some non-conventional therapies that some individuals find beneficial. It’s important to note that the effectiveness of these approaches can vary from person to person, and it’s advisable to consult with a healthcare professional before trying any new treatments. Here are some non-conventional therapies for neuropathic pain:
Are you a cancer survivor who struggles with nerve pain? If you would like to learn more about anti-cancer nutritional supplementation send me an email- David.PeopleBeatingCancer@gmail.com
Hang in there,
“Among the most difficult types of pain to alleviate is neuropathic pain, pain that is usually caused by damage to nerves in various body tissues, including skin, muscle and joints. It can cause patients to suffer feelings like electric shocks, tingling, burning or stabbing. Diabetes, multiple sclerosis, chemotherapy drugs, injuries and amputations have all been associated with neuropathic pain, which is often chronic, sometimes unrelenting and affects millions of people worldwide. Many of the available pain medications are only moderately effective at treating this type of pain and often come with serious side effects, as well as risk of addiction…
“We found it to be an effective painkiller, and the effects were rather long-lived,” said Stephen Martin, the June and J. Virgil Waggoner Regents Chair in Chemistry at The University of Texas at Austin and co-corresponding author of the paper. “When we tested it on different models, diabetic neuropathy and chemotherapy-induced neuropathy, for example, we found this compound has an incredible beneficial effect…”
The new compound, dubbed FEM-1689, does not engage opioid receptors in the body, making it a possible alternative to existing pain medications linked to addiction. In addition to reducing sensitivity, the compound can help regulate the integrated stress response (ISR), a network of cellular signaling that helps the body respond to injuries and diseases. When well regulated, the ISR restores balance and promotes healing. When it goes awry, the ISR can contribute to diseases such as cancer, diabetes and metabolic disorders…”
“Significance- Neuropathic pain is a major medical problem that is poorly treated with existing therapeutics. Our findings demonstrate that targeting σ2R/TMEM97 with a modulator reduces pain hypersensitivity in a mouse model with exquisite selectivity.
We also identify integrated stress response (ISR) inhibition as a potential mechanism of action that links the receptor to cellular signaling events that have preclinical and clinical validation for pain relief. Our work suggests that σ2R/TMEM97 can be selectively engaged by specific small molecules to produce ISR inhibition in a subset of cells that are critical for neuropathic pain. σ2R/TMEM97-targeted therapeutics thus have the potential to offer effective pain relief without engagement of opioid receptors…
We and others have shown that σ2R/TMEM97 ligands alleviate mechanical hypersensitivity in mouse neuropathic pain models with a time course wherein maximal antinociceptive effect is approximately 24 h following dosing. We sought to understand this unique antineuropathic pain effect by addressing two key questions:
These results validate σ2R/TMEM97 as a promising target for further development for the treatment of neuropathic pain…
Management of neuropathic pain is a major clinical challenge because available drugs not only have limited efficacy, but they also elicit serious side effects…